Summary of Fuxiang Pharmaceutical Conference Call Company Overview - Fuxiang Pharmaceutical is the largest supplier of sulbactam and the second-largest supplier of tazobactam globally, focusing on the production of antibiotic intermediates and active pharmaceutical ingredients since 2002 [2][5][22]. Industry Insights - The demand for energy storage and power batteries has significantly increased, leading to a rise in prices for VC (Vinyl Carbonate) and FEC (Fluoroethylene Carbonate) products, supported by government policies [2][3]. - The VC additive market has seen a collective shutdown for maintenance by key players, impacting supply by approximately 20,000 tons [8][10]. Key Points Production Capacity and Expansion Plans - Fuxiang plans to expand VC production capacity to 10,000 tons and FEC to 5,000 tons by Q2 2026, with environmental facilities already prepared for rapid expansion [2][4]. - Current VC production capacity is 8,000 tons, with a cost control below 50,000 yuan per ton, while market prices have surged to around 140,000 yuan [3][14]. Financial Performance and Cost Management - The price of LPA (a key raw material) has decreased from 280,000-300,000 yuan per ton to 160,000-170,000 yuan, significantly improving the gross margins for sulbactam and tazobactam [5][22]. - The company has implemented new processes to reduce costs by approximately 15% and has proprietary technology that is significantly cheaper than external sourcing [24][25]. Market Demand and Product Development - Fuxiang maintains an optimistic outlook on the downstream demand for sulbactam and tazobactam, with annual growth projected in the single digits [22]. - The introduction of new drugs has driven growth in the raw material intermediates market [22]. Microbial Protein and Agricultural Projects - Fuxiang is the first company in China to achieve industrialization of filamentous fungal protein at a scale of over 1,000 tons, with plans to expand to 20,000 tons by 2026 [6][27]. - The company is also developing a water-soluble fertilizer project, expected to yield significant benefits upon completion [28][29]. Competitive Landscape - The competitive landscape in the VC additive market is intense, with Fuxiang's main customers including Tianqi Materials and New Zobang, although specific sales proportions were not disclosed [13]. - The company is well-positioned to respond to market fluctuations due to its existing infrastructure and rapid approval processes for expansion [16][17]. Future Outlook - The company anticipates a new price equilibrium in the market, with strategies in place to maintain competitiveness regardless of price fluctuations [18]. - Fuxiang is closely monitoring developments in solid-state battery materials but currently has no active projects in that area [30]. Additional Insights - The microbial protein market is expected to grow due to its nutritional advantages over plant proteins, including zero cholesterol and low sugar content [30]. - The company has made significant investments in patent protection and certifications to support its strategic direction in microbial protein and other innovative products [7].

Group 1: Market Trends and Demand - The price of VC has rapidly increased, driven by the growth in demand for energy storage and power batteries, with current prices around 50,000 CNY/ton [2][3] - In the first half of 2025, the cumulative sales of power batteries reached 485.5 GWh, a year-on-year increase of 51.6% [3] - The shipment of lithium batteries for energy storage in China was 265 GWh in the first half of 2025, showing a year-on-year growth of 128% [3] Group 2: Production Capacity and Expansion Plans - The company currently has a production capacity of 8,000 tons/year for VC and 4,000 tons/year for FEC [4] - Plans are in place to increase VC production capacity to 10,000 tons/year by Q2 2026, with potential future expansions to 20,000 tons/year for VC and 5,000 tons/year for FEC depending on market demand [4] Group 3: Pricing and Profitability of Pharmaceutical Products - The procurement price of 6-APA has decreased by 38% compared to the end of 2024, which is expected to enhance the gross margin of the pharmaceutical manufacturing business [6] - The sales revenue from hezobactam and sulbactam is projected to account for approximately 40% of the company's total revenue in 2024 [6] Group 4: Market Outlook for Pharmaceutical Products - The sales of piperacillin-tazobactam injection exceeded 7 billion CNY in 2023, while the sales of cefoperazone-sulbactam injection surpassed 9 billion CNY, marking a year-on-year growth of 13.39% [6] - New drug approvals are expected to drive demand for upstream raw materials and intermediates, opening new growth avenues for the company [6] Group 5: Microbial Protein Production and Future Plans - The company has an existing production capacity of 1,200 tons/year for microbial protein and is accelerating the construction of a project with a planned capacity of 200,000 tons/year [9] - The microbial protein production process is efficient, sustainable, and free from antibiotics, with applications in various sectors including "meat alternatives" and health products [10] Group 6: Advantages of Amino Acid Water-Soluble Fertilizers - The amino acid water-soluble fertilizers contain essential amino acids and have shown significant effects on plant growth and metabolism [11] - The market outlook is promising due to national policies promoting the reduction of chemical fertilizers and the innovation of green inputs [11]

Core Viewpoint - The company is experiencing significant growth in demand for its products, particularly in the VC and FEC segments, driven by the rapid expansion of the energy storage and power battery markets, alongside strategic capacity expansion plans [1][2]. Group 1: Market Demand and Pricing - Recent rapid increases in VC product prices are attributed to the growing demand from energy storage and power batteries, with VC prices around 50,000 yuan/ton [1]. - In the first half of 2025, the cumulative sales of power batteries reached 485.5 GWh, a year-on-year increase of 51.6%, while the shipment of energy storage lithium batteries was 265 GWh, up 128% year-on-year [1]. - The energy storage market in China is expected to exceed 500 GWh in scale, with a year-on-year growth rate of over 50% anticipated [1]. Group 2: Production Capacity and Expansion Plans - The company currently has a production capacity of 8,000 tons/year for VC and 4,000 tons/year for FEC, with plans to increase VC capacity to 10,000 tons/year by Q2 2026 [2]. - Future plans include increasing VC capacity to 20,000 tons/year and FEC capacity to 5,000 tons/year, depending on market demand and industry capacity releases [2]. Group 3: Cost Management and Profitability - The company is focused on reducing production costs for its VC products through technological improvements and has a strong position in cost control within the industry [3]. - The procurement price of 6-APA has decreased by 38% compared to the end of 2024, which is expected to enhance the gross margin of the company's pharmaceutical manufacturing business [4]. Group 4: Product Development and Market Position - The company is the largest global supplier of sulbactam and a major supplier of tazobactam, with ongoing efforts to expand production capacity for these products [5]. - The company has achieved significant milestones in the microbial protein sector, with a current capacity of 1,200 tons/year and plans for a project that will scale up to 20,000 tons/year [6]. Group 5: Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 769 million yuan, a year-on-year decrease of 21.24%, and a net profit attributable to shareholders of -62.75 million yuan [7]. - The company's gross margin stands at 12.05%, with a debt ratio of 51.15% [7].

Group 1: Market Trends and Demand - The price of VC has rapidly increased due to the growing demand from energy storage and power batteries, influenced by macro policies and supply-demand changes [2][3] - In the first half of 2025, the cumulative sales of power batteries reached 485.5 GWh, a year-on-year increase of 51.6%, while the shipment of energy storage lithium batteries was 265 GWh, up 128% year-on-year [3] Group 2: Production Capacity and Expansion Plans - The company currently has a production capacity of 8,000 tons/year for VC and 4,000 tons/year for FEC, with plans to increase VC capacity to 10,000 tons/year by Q2 2026 [3] - Future plans include increasing VC and FEC production capacities to 20,000 tons/year and 5,000 tons/year, respectively, depending on market demand [3] Group 3: Cost Management and Efficiency - The company is leveraging its experience in chemical processes to control production costs effectively, with VC product costs expected to decrease further as capacity increases [4] - The procurement price of 6-APA has decreased by 38% compared to the end of 2024, which is anticipated to enhance the gross margin of the pharmaceutical manufacturing business [6] Group 4: Product Portfolio and Market Position - The company is the largest global supplier of Sulbactam and a major supplier of Tezobactam, with a significant market share and quality assurance [5][6] - The company is expanding its production capacity for Piperacillin, which is in high demand due to increased terminal demand [7] Group 5: New Product Development - The company is the first in China to achieve large-scale industrialization of filamentous fungal protein, with a current capacity of 1,200 tons/year and plans for a 200,000 tons/year project [7] - The new protein has passed technical reviews and is awaiting regulatory approval, which will enable the company to expand its microbial protein business significantly [7]

Core Viewpoint - Company is a major global supplier of tazobactam and has successfully completed the qualification process for downstream customers, which will enhance production capacity and market competitiveness [1] Group 1: Product Supply and Market Position - Company is the largest global supplier of sulbactam and the only domestic supplier certified by international standards, with sulbactam products currently experiencing a price increase [1] - Company is expanding the production capacity of piperacillin, which can be combined with tazobactam and sulbactam to form compound preparations, indicating a broad market demand [1] Group 2: Production Cost and Innovation - Company is one of the few domestic manufacturers with a full industry chain layout for carbapenem products, and the market price for carbapenem products is at a historical low, with limited room for further price declines [1] - Company is collaborating with a research team to develop a continuous flow enzyme method, which is expected to reduce the cost of carbapenem products by 15%-20% [1]

Core Viewpoint - Fuxiang Pharmaceutical (300497) announced that its main pharmaceutical products, tazobactam and sulbactam, are expected to account for approximately 40% of the company's revenue in 2024 [1] Group 1 - The main raw material for tazobactam and sulbactam is 6-APA, which has seen a price decrease of 38% as of November 3, 2025, compared to the end of 2024 [1] - The decline in 6-APA prices is anticipated to effectively enhance the gross profit margin of the company's pharmaceutical manufacturing business [1]

Production Capacity and Expansion Plans - The company currently has a production capacity of 8,000 tons/year for VC products and 4,000 tons/year for FEC products, with plans to increase VC capacity to 10,000 tons/year by Q2 2026 through technical upgrades [2][3] - Future capacity increases for VC and FEC products will depend on market demand and industry capacity releases, with potential targets of 20,000 tons/year for VC and 5,000 tons/year for FEC [2] Impact of Raw Material Price Changes - The price of 6-APA, a key raw material for the company's main pharmaceutical products, has decreased by 38% as of November 3, 2025, which is expected to enhance the gross margin of the pharmaceutical manufacturing business [3] - The company's pharmaceutical products, including Hezobactam and Shubactam, account for approximately 40% of total revenue in 2024 [3] Growth Opportunities in Pharmaceutical Business - The company is a major global supplier of Hezobactam and has successfully completed supplier qualification for its new production process, which is expected to reduce production costs and improve market competitiveness [4] - As the largest supplier of Shubactam, the company is experiencing a price increase trend for this product [4] - The company is expanding the production capacity of Piperacillin, which is a mainstream product with broad market demand [4] Synthetic Biology and Microbial Protein Initiatives - The company has become a pioneer in the domestic microbial protein industry, achieving a production capacity of 1,000 tons/year for filamentous fungal protein and is accelerating the construction of a project with an annual capacity of 200,000 tons for microbial protein and resource utilization [6] - The company has developed a new production strain with independent intellectual property rights and has applied for patents in nine countries, achieving international advanced levels in key production technologies [6][7] - The company’s microbial protein has received multiple international certifications, including HALAL and KOSHER, and is set to expand its market presence upon receiving new food ingredient registration [7][8] Environmental and Economic Benefits - The production process for the new protein not only efficiently converts raw materials but also produces high-value products like amino acid water-soluble fertilizers, contributing to cost reduction and economic benefits [8] - The company aims for zero emissions in its production processes, aligning with green manufacturing goals [8]

Group 1: Macro Strategy - The current A-share market resembles the early stages of the 2020-2021 bull market, indicating a slow bull phase driven by strategic funds, similar to the role of foreign capital in early 2020 [1][8] - The market is expected to follow a structural "innovation bull" trend in 2026, as new funds and improved performance from domestic institutions emerge [1][8] Group 2: Fixed Income Market - The bond market remains in a box range, with the central bank maintaining liquidity through reverse repos and net purchases of government bonds, while new redemption fee regulations may cause volatility [2][9] - The 10-year government bond yield is expected to continue a narrow fluctuation pattern, with potential opportunities arising from rapid interest rate increases due to new redemption fee regulations [2][9] Group 3: Company Analysis - Fuxiang Pharmaceutical - Fuxiang Pharmaceutical is set to benefit from a significant increase in the price of vinyl carbonate (VC), which has risen 63% from 4.75 million CNY/ton to 7.75 million CNY/ton due to increased demand in the energy storage sector [6][20] - The company has invested in projects to produce 6,000 tons of lithium battery additives annually, positioning itself as a leader in the industry [6][20] - The decline in the price of 6-APA, a key raw material, is expected to enhance the company's gross margin as high-cost inventory is consumed [6][20] Group 4: Company Analysis - Xiaogoods City - Xiaogoods City has acquired land to develop an integrated cultural and commercial complex, which is expected to expand its market presence and increase revenue and profit [7] - The projected net profit for 2025-2027 is 49.0 billion CNY, 61.6 billion CNY, and 72.8 billion CNY, reflecting growth rates of 59%, 26%, and 18% respectively [7]

Group 1: VC Price Increase and Company Benefits - The price of Vinyl Carbonate (VC) has risen to 77,500 yuan/ton as of November 12, marking a 63% increase from 47,500 yuan/ton on September 1, driven by increased demand in both domestic and overseas energy storage sectors [1] - The company is positioned to benefit from this price increase due to its leading production capacity in the industry, with ongoing projects to produce 6,000 tons of lithium battery additives and 10,000 tons of VC and 2,000 tons of FEC [1] - By mid-2025, the company is expected to achieve an annual production capacity of 8,000 tons of VC and 3,700 tons of FEC, further enhancing its competitive position in the market [1] Group 2: 6-APA Price Decline and Margin Improvement - The price of 6-APA, a key intermediate for antibiotics, has significantly decreased, dropping to 180 yuan/kg in October 2025, a 51% decline from January 2023, due to lower flu incidence and the resumption of old production capacities [2] - The company's main products, Shubatan and Tazobactam, are highly sensitive to 6-APA prices, with their production requiring 1.3 tons and 5 tons of 6-APA per ton, respectively [2] - As the company depletes its high-cost inventory, an increase in gross margin is anticipated, although this improvement has not yet fully reflected in financial statements [2] Group 3: Profit Forecast and Investment Rating - The company's revenue forecast for 2025-2026 has been adjusted downwards from 2 billion/2.52 billion yuan to 1.15 billion/1.49 billion yuan, with a projected revenue of 1.64 billion yuan in 2027 [3] - The net profit forecast for 2025-2026 has been revised from 150 million/250 million yuan to -60 million/190 million yuan, with a net profit of 240 million yuan expected in 2027 [3] - Despite these adjustments, the company maintains a "Buy" rating due to benefits from the VC price increase and the decline in 6-APA prices [3]

Group 1 - The stock price of Fuxiang Pharmaceutical on August 27 was 10.05 yuan, down 0.59 yuan or 5.55% from the previous trading day [1] - The company primarily engages in the research, production, and sales of active pharmaceutical ingredients and intermediates for anti-infection drugs, while also expanding into lithium battery electrolyte additives and synthetic biology microbial protein [1] - Fuxiang Pharmaceutical is the largest supplier of sulbactam globally and the only domestic supplier in the sulbactam field certified by international standards [1] Group 2 - According to the company's 2025 semi-annual report, it achieved operating revenue of 515 million yuan in the first half of the year, a year-on-year decrease of 24.6%, with a net profit attributable to the parent company of -6.91 million yuan, an improvement from a loss of 22.46 million yuan in the same period last year [1] - In the lithium battery electrolyte additive business, the company has established an annual production capacity of 8,000 tons for VC products and 3,700 tons for FEC products [1] - The company has a production capacity of 1,200 tons per year in the microbial protein sector and is constructing a project with an annual capacity of 20,000 tons [1] Group 3 - On August 27, the net inflow of main funds into Fuxiang Pharmaceutical was 17.78 million yuan, accounting for 0.39% of the circulating market value; over the past five days, the cumulative net inflow was 20.96 million yuan, representing 0.46% of the circulating market value [2]